The incidence and severity of injection-site lesions has decreased since the development of the Beef Quality Assurance program. The objective was to evaluate the route of administration and the pharmaceutical product on the impact on tenderness, collagen concentration, and lesion occurrence in muscles of chucks and rounds. A total of 144 yearling steers (initial BW = 383 ± 29.4 kg) were selected and transported to Oklahoma State University. Steers were blocked into 2 groups of 72 based on initial BW and were randomly allocated, within block, into pens of 6 head per pen (12 pens per block). Each pen was randomly assigned an injection protocol. On May 19, 2006 (d 0), steers were administered one of the following treatment injections: a standard Biobullet containing 100 mg of ceftiofur sodium (Naxel, Pfizer Inc., New York, NY); a traditional needle and syringe dose of ceftiofur sodium; a standard Biobullet containing BallistiVac infectious bovine rhinotracheitis (IBR; Titanium 5, SolidTech Animal Health, Newcastle, OK); a traditional needle and syringe dose of IBR; a traditional needle and syringe dose of Vira Shield 5 (Grand Laboratories Inc., Freeman, SD); a standard placebo Biobullet; or a traditional needle and syringe dose of sterile water. Percentage of samples with an identifiable lesion did not differ by drug administered or injection method. Warner-Bratzler shear force values of lesion center cores in chucks tended to be different (P = 0.07) from cores from the control steaks and at 2.54 and 5.08 cm away from the lesion center. Lesion centers from the Biobullet-BallistiVac IBR had a Warner-Bratzler shear force value of 7.01 kg, which was greater (P < 0.05) than values for lesion centers from chucks injected with a Biobullet-placebo (6.27 kg) or needle-ceftiofur sodium (5.08 kg). No significant differences (P > 0.10) were observed in the total collagenous connective tissue in samples extracted from the chuck or round. The comparison of lesion site and control (nonlesion site) samples for lipid concentration showed no significant difference (P > 0.10) among treatments in the round. It was concluded the Biobullet did not create a greater occurrence of lesions in the muscles of the chuck and round. The Biobullet is not an appropriate injection method for the round of beef cattle because it caused tissue damage similar to a needle injection. However, the Biobullet can be used effectively in neck (chuck) applications without additional negative effects on tenderness.
INTRODUCTION
The National Cattlemen's Beef Association has worked for more than 15 yr on developing the Beef Quality Assurance program to resolve quality challenges such as tissue damage and tenderness complications created by injection-site damage in the top sirloin butt and in muscles of the round (Roeber et al., 2001) . George et al. (1997) demonstrated that subprimals that contained lesions (visible or nonvisible) had greater shear force values (P < 0.01) and greater tenderness variation than noninjected control subprimals. As a result of this and similar research, greater influence was placed on moving injections to the neck region for all methods of administration of pharmaceutical products.
More recently, SolidTech Animal Health Inc. (Newcastle, OK) has devised a method for injectable ad-ministration of pharmaceutical products that uses an air-powered delivery system and biodegradable projectiles containing products such as freeze-dried ceftiofur sodium antibiotic. These Biobullets penetrate into the muscle of the animal and begin to be absorbed (R. Hansen, SolidTech Animal Health, personal communication, 2007) . Morgan et al. (2004) conducted a preliminary study on the impact of Biobullets on tissue damage and tenderness in beef rounds. They documented limited visible tissue damage in cattle treated with Biobullets at 21, 28, and 35 d before slaughter.
Although the research conducted by Morgan et al. (2004) indicated that the Biobullet method of administering ceftiofur sodium, when used at least 30 d before slaughter, led to no detectable increase in tissue damage or tenderness, no comparisons between the Biobullet and traditional administration techniques have been made. The current study was conducted to evaluate the impact of administration methods and use of various pharmaceuticals on lesion occurrence, tenderness, and collagen content in muscles of the round and muscles of the chuck.
MATERIALS AND METHODS
Administration of products followed the protocol approved by the Institutional Animal Care and Use Committee at Oklahoma State University, which included documenting previous animal handling and vaccination administration for all personnel.
Cattle
Steers (n = 144, initial BW = 383 ± 29.4 kg) of known treatment history were selected and transported to the Willard Sparks Beef Cattle Research Center at Oklahoma State University. Steers were considered for inclusion in the study based on having no prior treatments for bovine respiratory disease, having a British × Continental phenotype, and BW. Cattle were managed by the owner from birth and were documented with animal health records as having had no previous injections in the neck or round muscles on the right side before the initiation of the trial. No previous injections had been given to any of the cattle on the right side at the initiation of the trial. Beginning on May 17, 2006, steers were individually weighed on 2 consecutive days for allocation. All steers had been fed a 94% concentrate diet for at least 30 d before initial weighing. Steers were blocked based on initial BW into 2 groups of 72 animals and randomly allocated, within block, into 12 pens of 6 animals (6 pens per block). Each pen was randomly assigned to an injection treatment protocol. On May 19, 2006 (d 0) , steers were administered the appropriate treatment injection: a standard Biobullet containing 100 mg of ceftiofur sodium (Naxel, Pfizer Inc., New York, NY; one Biobullet administered on the right side and 2 Biobullets administered on the left side of the steer); a traditional needle and syringe dose of ceftiofur sodium (3.5 mL using a 2.54-cm, 16-gauge needle); a standard Biobullet containing BallistiVac infectious bovine rhinotracheitis (IBR; Titanium 5, SolidTech Animal Health; 1 Biobullet administered on the right side and 2 Biobullets administered on the left side of the steer); a traditional needle and syringe dose of IBR (2 mL using a 2.54-cm, 16-gauge needle); a traditional needle and syringe dose of Vira Shield 5 (5 mL s.c. using a 1.59-cm, 16-gauge needle; Grand Laboratories Inc., Freeman, SD); a standard Biobullet containing a placebo (1 empty Biobullet administered on the right side, and 2 empty Biobullets administered on the left side of the steer); and a traditional needle and syringe containing a placebo (sterile water, 5 mL using a 2.54-cm, 16-gauge needle). Three Biobullets were administered to meet the same dosage of vaccine used in needle administration, based on label requirements and the BW of the animal at the time of administration. However, only 1 Biobullet was administered on the right side of the animal, the side dedicated to this study, to determine the effect of Biobullet vs. needle injection on tissue damage and subsequent tenderness. For all injections, cattle were restrained in a standard squeeze chute.
The target location for the injections given was in the serratus ventralis muscle in the chuck for neck injections and in the biceps femoris muscle in the outside round for round injections. For the remainder of the trial, steers were fed twice daily a 95% concentrate finishing diet ad libitum. Steers in block 2 were shipped to slaughter on d 101, and steers in block 1 were shipped on d 122.
Treatment
For all treatments, cattle were restrained in a standard squeeze chute and were administered the dosage intramuscularly in either the neck (chuck/prescapular) or round (lower quarter) region. A SolidTech Animal Health representative administered all Biobullet dosages at a distance of 6.1 m, whereas Oklahoma State University staff administered all other injections.
Slaughter and Meat Samples
After completion of the finishing period, steers (n = 144) were transported to Emporia, Kansas, for slaughter at a commercial abattoir. Cattle were tracked through the facility from the immobilization box to the rapidchilling cooler by using tag transfer to maintain animal identity. After slaughter and chilling, trained Oklahoma State University personnel recorded carcass data, and tagged and identified the rounds and chucks, which was done to maintain carcass identity through fabrication. Carcasses were then fabricated according to Institutional Meat Purchase Specifications (IMPS; USDA, 1996) . Outside round flats (biceps femoris muscle, IMPS No. 171a; n = 69) and 2-piece boneless chucks (IMPS No. 115; n = 60) from the right side of carcasses were col-lected. Not all chucks or rounds were collected because of excess trimming on the slaughter floor (n = 1 round, 2 chucks), carcasses held for regrading by the plant (n = 1 round, 6 chucks), or primals losing tags during the fabrication process (n = 1 round, 4 chucks). Subprimals were vacuum-packaged and transported back to the Oklahoma State University Food and Agricultural Products Center. Subprimals where then aged for 14 d at 3 ± 1°C.
After aging, rounds (n = 69) and chucks (n = 60) were fabricated into 2.54-cm steaks across the muscle fiber orientation on a sanitized commercial band saw. Personnel previously involved in the evaluation of injection-site lesions observed and palpated each steak for the presence of injection-site lesions in the serratus ventralis or biceps femoris muscles when evaluating chucks or rounds, respectively. On identification, lesions were verbally depicted by using a 5-point classification system as described by Dexter et al. (1994) , which categorizes lesions as cystic, scar with nodules, metallic scar, clear scar, or woody callus. If a lesion was present, the center of the lesion was identified such that steaks representing areas that were 2.54, 5.08, and 7.62 cm away from the lesion center could be selected for additional evaluation. Another steak was acquired to represent the same muscle as far from the center as possible; this steak was deemed a control steak. An additional control steak and lesion steak were also taken for proximate and hydroxyproline analysis. If no lesion was found in the subprimal, steaks were selected from the region where the injection was given and matched to where lesions were identified in other samples because all injections were given in the same location, along with an additional control steak, for Warner-Bratzler shear force (WBSF) testing, proximate analysis, and collagen determination. After steaks were labeled with the sample identification and the distance from the lesion center was characterized, they were vacuum-packaged and frozen for further analysis.
WBSF
Steaks were allowed to temper for 24 h at 4°C before cooking. Steaks were randomly assigned to cooking order across treatment group, and broiled on an impingement oven (model 11132-00-A, Lincoln Impinger, Fort Wayne, IN) at 180°C to an internal temperature of 70°C. Internal steak temperatures were monitored by using copper constantan thermocouples (model OM-202, Omega Engineering Inc., Stamford, CT). After cooking, steaks were allowed to cool for 2 h to 25°C before coring. Four cores, 1.27 cm in diameter, were removed parallel to the muscle fiber orientation for each WBSF measurement, with the exception of the lesion center, where only one core was obtained. Lesion center cores were obtained from the same relative location in treated and control muscles. Following the procedure outlined by George et al. (1995) , a core was removed from the immediate area near the lesion center, and 4 additional cores were removed at each radial distance of 2.54, 5.08, and 7.62 cm from the lesion location; cores were obtained from the center steak as well as serial steaks to reach appropriate distances. In chucks, when lesions were identified in the seam fat between muscles, the serratus ventralis was used for WBSF analysis. Each core was sheared once by a Warner-Bratzler head attached to an Instron Universal Testing Machine (model 4502, Instron Corp., Canton, MA) at a crosshead speed of 200 mm/min. Peak force (kg) of each core was recorded by an IBM PS2 instrument (Model 55 SX) using software provided by the Instron Corp.
Proximate Analysis
Proximate analysis of the samples was performed in duplicate and averaged according to the procedures outlined by AOAC (1990) . Each sample was frozen individually in liquid nitrogen and pulverized to a powder in a Waring blender (Dynamics Co. of America, New Hartford, CT). Three grams of the powdered sample was placed in filter paper, dried at 100°C for 24 h, desiccated for 1 h, and then reweighed to determine moisture. After moisture determination, each sample was placed in a Soxhlet apparatus for 24 h for ether extraction of lipids, followed by drying at 100°C for no more than 12 h. Each sample was desiccated and reweighed to calculate lipid content.
Collagen Determination
Hydroxyproline is quantitatively determined as a measure of collagenous material in meat and meat products. Collagenous connective tissue contains 12.5% hydroxyproline when a collagen-protein factor of 6.25 is used (Kolar, 1990) . To determine the collagen content, a sample was freeze-dried using liquid nitrogen and powdered in a blender as described above. A 4-g sample was then hydrolyzed using sulfuric acid at 105°C for approximately 16 h. On completion of heating, the solution was filtered and diluted using the protocol listed by Kolar (1990) . The hydroxyproline was oxidized using chloramine-T. Once a reddish-purple color developed, the sample was measured photometrically at 560 nm. On retrieving absorption data from the spectrophotometer, hydroxyproline content (H) was calculated as follows: H, g/100 g = (h × 2.5)/(m × V), where h is hydroxyproline (µg/2 mL of filtrate), read from the calibration curve; m is the weight of the sample (grams); and V is the volume (mL) of filtrate taken for dilution to 100 mL for the hydrolysis step. The result from this calculation was an arithmetic mean of 2 calculated values for each sample. In calculating the collagenous connective tissue content (B), the following formula was used: B, g/100 g = H × 8. As stated previously, collagenous connective tissue contains 12.5% hydroxyproline if the nitrogen-to-protein factor is 6.25.
Statistical Analysis
All postslaughter results were analyzed by using the GLM procedure (PROC MIXED, SAS Inst., Inc., Cary, NC), with the individual animal as the experimental unit. Data were analyzed to determine the effect of pharmaceutical product, method of administration, and the pharmaceutical product × method of administration interaction on lesion occurrence and WBSF, fat, and collagen content at each sample location (control steak, lesion site or center, and each distance from the lesion). Means were separated when a significant F-test (α = 0.05) was observed. Means were separated by us- 2 n = 16 for placebo; n = 17 for ceftiofur sodium; n = 18 for IBR; n = 30 for Biobullet; n = 21 for needle. Placebo = administration of sterile water or an empty Biobullet (SolidTech Animal Health, Newcastle, OK); ceftiofur sodium = injection of ceftiofur sodium (Naxel, Pfizer Inc., New York, NY) via needle injection or Biobullet administration; IBR = injection of infectious bovine rhinotracheitis vaccine (SolidTech Animal Health) via needle injection or Biobullet administration; Biobullet = administration of pharmaceutical product via the Biobullet; needle = administration of pharmaceutical product via traditional needle injection. Sample excised from the same muscle far away from the lesion site. a-c Within a column, means without a common superscript letter differ (P < 0.05). 1 n = 34 of the 60 chucks were identified with visible injection-site lesions. 2 Placebo = administration of sterile water or an empty Biobullet (SolidTech Animal Health, Newcastle, OK); ceftiofur sodium = injection of ceftiofur sodium (Naxel, Pfizer Inc., New York, NY) via needle injection or Biobullet administration; IBR = injection of infectious bovine rhinotracheitis vaccine (SolidTech Animal Health) via needle injection or Biobullet administration; Biobullet = administration of pharmaceutical product via the Biobullet; needle = administration of pharmaceutical product via traditional needle injection.
3 Sample excised from the same muscle far away from the lesion site. 4 Probability of the F-test.
ing a pairwise t-test. Percentage incidence of lesions was analyzed by using the chi-squared procedure of SAS.
RESULTS AND DISCUSSION

Lesion Presence
Results of visual palpation and inspection of 69 rounds and 60 chucks identified a lesion in 71.83% of all placebo treatment rounds. This was similar to rounds injected with sodium ceftiofur, 70.83% of which had a visual lesion present (Table 1) . Of the rounds injected with IBR, 77.83% had a visual lesion present, which was the greatest numerical percentage of all rounds, although this incidence percentage was not different (P > 0.05) from the incidence with other pharmaceutical products. The placebo chucks and chucks injected with IBR had visual lesion incidence percentages of 52.60 and 52.36%, respectively. The greatest numerical lesion percentage in chucks (65.04%) occurred in chucks injected with ceftiofur sodium.
Although lesion occurrence was not significantly different (P > 0.05) between the 2 methods of administration, 83.33% of rounds injected with a Biobullet had a visible lesion, as compared with 63.66% of rounds injected by using a needle. Of the chucks injected with a Biobullet, 56.25% possessed a lesion, compared with 57.08% of chucks injected with a needle. However, this contradicts findings by Morgan et al. (2004) , which indicated that cattle receiving a Biobullet injection at least 21 d before slaughter had no (P = 0.88) detectable injection site lesion in the biceps femoris.
The types of lesions found in the chucks and rounds included clear scars and woody calluses, as well as metallic and nodular lesions. The vast majority of lesions identified were clear scars (n = 108 of 129; 83.7%) in both the chuck and round. In the 2-piece chucks evaluated, 19.7% of lesions were found in the clod, as compared with 80.3% lesions identified in the chuck roll. Lesions found in the chuck roll and clod were commonly found in seam fat between the muscles, whereas lesions found in the round were generally found in lean muscle tissue. In several instances, clear lesions found in the eye of round were long and narrow white tracks going across the grain of the muscle fiber. These results indicated the occurrence of injection-site lesions in beef subprimals, regardless of the drug administered or the injection method. Because of the occurrence of 2 n = 10 for placebo; n = 13 for ceftiofur sodium; n = 11 for IBR; n = 17 for Biobullet; n = 17 for needle. Placebo = administration of sterile water or an empty Biobullet (SolidTech Animal Health, Newcastle, OK); ceftiofur sodium = injection of ceftiofur sodium (Naxel, Pfizer Inc., New York, NY) via needle injection or Biobullet administration; IBR = injection of infectious bovine rhinotracheitis vaccine (SolidTech Animal Health) via needle injection or Biobullet administration; Biobullet = administration of pharmaceutical product via the Biobullet; needle = administration of pharmaceutical product via traditional needle injection. tissue damage with injection, Beef Quality Assurance guidelines outline that all injections should be given in the neck region, subcutaneously if possible, and that needles should be changed every 20 animals to limit tissue damage in highly valued cuts of the rib, loin, and round (National Cattlemen's Beef Association, 2008) .
WBSF
Warner-Bratzler shear force was not affected by the drug administered, the injection method, or their interaction in beef rounds in the control steak, lesion center, or at distances 2.54, 5.08, or 7.62 cm away from the lesion center (Table 2 ). However, there was a tendency (P = 0.11) for IBR injections to cause an increase in WBSF values or to result in decreased tenderness, as compared with the placebo and ceftiofur sodium injections (Table 2 ).
An interaction between drug administered and method of injection was observed in beef chuck lesion center steaks and steaks that were 7.62 cm away from the lesion center. Lesion centers from the BiobulletBallistiVac IBR had a WBSF value of 7.01 kg, which was significantly tougher (P < 0.05) than lesion centers from chucks injected with a needle-IBR, needleplacebo, or Biobullet-ceftiofur sodium injection, which had WBSF values of 4.66, 4.61, and 3.81, respectively (Table 3) . However, this contradicts research conducted by Morgan et al. (2004) , in which only steers treated with a Biobullet injection at 7 or 14 d before slaughter displayed the presence of injection lesions in the biceps femoris; thus, no detrimental effects on beef tenderness would likely be realized with the Biobullet treatment 21 d or more before slaughter. Although the results of Morgan et al. (2004) agreed with those when using ceftiofur sodium, the same did not hold true with injections of IBR, which, when administered with the Biobullet, resulted in tougher steaks than when injected with a needle.
Neither the drug administered, the injection method, nor their interaction had an impact (P > 0.05) on WBSF values for chuck steaks taken at 2.54 and 5.08 cm away from the lesion center (Table 4) . However, chuck steaks from all Biobullet treatment groups, as well as from the needle-ceftiofur sodium and needle-IBR injection groups, had WBSF values that were more tender (P < 0.05) at 7.62 cm away from the lesion center as compared with the needle-placebo treatment group, which resulted in the toughest steaks at 7.62 cm from the lesion center (Table 3) .
Collagen and Lipid Content
Tenderness is affected by the amounts of collagen, connective tissue, and lipid that occur in a muscle. When an injection is given and tissue damage occurs, the healing process involves the deposition of connective tissue, collagen, and lipids in and around the wound (George et al., 1995) . No significant differences (P > 0.05) were found in the total collagenous connective tissue in samples extracted from muscles in chucks or rounds (Table 5 ) in the control steaks or lesion steaks.
Comparison between the lesion site and control samples for lipid concentration showed no significant difference (P > 0.05) for drug administered or injection method in the round (Table 6 ). These results contradict the findings of Morgan et al. (2004) and George et al. (1995) documenting that lipid content is greater at the lesion site than in the control steak.
Tenderness is a key factor in satisfaction for beef consumers. If injection lesions are present, it can affect a large portion of that particular cut of meat, and consequently increase the odds of an unpleasant eating experience and result in a dissatisfied customer (George et al., 1997) . Although injection-site lesions are decreasing in prevalence, new technologies have given producers an alternative to the traditional needle and syringe. Using these new methods of administration may ease Within a row and column subset (drug administered or injection method), means without a common superscript letter differ (P < 0.05).
1 n = 45 rounds; n = 24 chucks.
2 Placebo = administration of sterile water or an empty Biobullet (SolidTech Animal Health, Newcastle, OK); ceftiofur sodium = injection of ceftiofur sodium (Naxel, Pfizer Inc., New York, NY) via needle injection or Biobullet administration; IBR = injection of infectious bovine rhinotracheitis vaccine (SolidTech Animal Health) via needle injection or Biobullet administration; Biobullet = administration of pharmaceutical product via the Biobullet; needle = administration of pharmaceutical product via traditional needle injection. the stress of livestock of being handled several times for repeated vaccinations. Because the use of Biobullet technology does not cause additional tissue damage, when compared with tradition needle injection, in valuable muscles of the chuck and round, it can be used effectively in neck (chuck) applications without additional negative effects on tenderness. However, the Biobullet cannot be recommended for use in the round or any other location behind the point of the shoulder because it does not comply with Beef Quality Assurance guidelines.
